OBJECTIVES Although a single nucleotide polymorphism in a specific receptor for lysophosphatidylserine, a lysophospholipid mediator involved in the immune system, is reportedly associated with Graves' disease, the association between lysophosphatidylserine and thyroid disorders remains to be elucidated. Therefore, we aimed to investigate the association between the level of phosphatidylserine-specific phospholipase A1 (PS-PLA1), which produces lysophosphatidylserine, and thyroid disorders. METHODS We measured serum PS-PLA1 levels in the patients with various thyroid disorders (n = 120) and normal subjects (n = 58). RESULTS We observed that the serum PS-PLA1 levels were higher in the subjects with Graves' disease, subacute thyroiditis, or silent thyroiditis, while they were not modulated in the patients with hypothyroidism. The serum PS-PLA1 levels were strongly correlated with the levels of thyroid hormones, especially in the subjects with Graves' disease. Moreover, we found that the serum PS-PLA1 levels were lowered by treatment with anti-thyroid reagents in subjects with Graves' disease and that the changes in PS-PLA1 were strongly correlated with those in thyroid hormones. CONCLUSION These results suggest that PS-PLA1 might be a novel target in the treatment of hyperthyroidism, especially Graves' disease, and that its measurement might be useful as a supplementary diagnostic test for thyroid function.

中文翻译：

---

甲亢中磷脂酰丝氨酸特异性磷脂酶A1水平升高。

目的尽管据报道，参与免疫系统的溶血磷脂介导的溶血磷脂酰丝氨酸的特异性受体中的单核苷酸多态性与格雷夫斯病相关，但溶血磷脂酰丝氨酸与甲状腺疾病之间的关联仍有待阐明。因此，我们旨在研究产生溶血磷脂酰丝氨酸的磷脂酰丝氨酸特异性磷脂酶A1（PS-PLA1）水平与甲状腺疾病之间的关系。方法我们测量了各种甲状腺疾病（n = 120）和正常受试者（n = 58）患者的血清PS-PLA1水平。结果我们观察到，在患有Graves病，亚急性甲状腺炎或无症状甲状腺炎的受试者中，血清PS-PLA1水平较高，而在甲状腺功能减退症患者中则没有调节。血清PS-PLA1水平与甲状腺激素水平密切相关，尤其是在患有Graves病的受试者中。此外，我们发现在格雷夫斯病患者中，通过抗甲状腺药物治疗可降低血清PS-PLA1水平，并且PS-PLA1的变化与甲状腺激素的变化密切相关。结论这些结果表明PS-PLA1可能是甲亢，特别是Graves病治疗中的新靶标，其测量结果可能对甲状腺功能的补充诊断测试有用。我们发现，在格雷夫斯病患者中，通过抗甲状腺药物治疗可降低血清PS-PLA1水平，并且PS-PLA1的变化与甲状腺激素的变化密切相关。结论这些结果表明PS-PLA1可能是治疗甲亢，尤其是Graves病的一种新型靶标，其测量结果可能对甲状腺功能的补充诊断测试有用。我们发现，在格雷夫斯病患者中，通过抗甲状腺药物治疗可降低血清PS-PLA1水平，并且PS-PLA1的变化与甲状腺激素的变化密切相关。结论这些结果表明PS-PLA1可能是治疗甲亢，尤其是Graves病的一种新型靶标，其测量结果可能对甲状腺功能的补充诊断测试有用。